XBRANE BIOPHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2295 SEK | +20.54% |
|
+13.61% | -97.70% |
| May. 10 | Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar | MT |
| May. 02 | Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director | CI |
Evolution of the average Target Price on Xbrane Biopharma AB
Price target over the last 5 years
History of analyst recommendation changes
8b082008166.6nX7upauzIJRsDYlkPS7t3eiq7tj6DW_t8azeag92UQ.pCC-_cPWtMUC3FV8_rn-1UfH2twWpm3U55KHTN1yqweQALbRopem1D_dUQ~478c92a5670c182186aa4deff07fe8fe
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.2295
SEK
Average target price
0.625
SEK
Spread / Average Target
+172.33%
High Price Target
0.65
SEK
Spread / Highest target
+183.22%
Low Price Target
0.6
SEK
Spread / Lowest Target
+161.44%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
C+
EPS Revisions
- Stock Market
- Equities
- XBRANE Stock
- Consensus Xbrane Biopharma AB